Thrombogenics DRC - A Phase 1, open-label, multicenter, dose escalation study to evaluate the safety and tolerability of a single intravitreal injection of THR-149 for the treatment of diabetic macular edema (DME)

Administered By

Awarded By

Contributors

Start/End

  • March 27, 2018 - March 27, 2022